WO2023128905A1 - Composition pharmaceutique comprenant du tolvaptan amorphe - Google Patents
Composition pharmaceutique comprenant du tolvaptan amorphe Download PDFInfo
- Publication number
- WO2023128905A1 WO2023128905A1 PCT/TR2021/051629 TR2021051629W WO2023128905A1 WO 2023128905 A1 WO2023128905 A1 WO 2023128905A1 TR 2021051629 W TR2021051629 W TR 2021051629W WO 2023128905 A1 WO2023128905 A1 WO 2023128905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- tolvaptan
- screened
- pharmaceutically acceptable
- Prior art date
Links
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960001256 tolvaptan Drugs 0.000 title claims abstract description 64
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 40
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 19
- 238000007908 dry granulation Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 42
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 18
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 229920000881 Modified starch Chemical class 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- 235000012222 talc Nutrition 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 229960001375 lactose Drugs 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010021036 Hyponatraemia Diseases 0.000 claims description 5
- 229920002472 Starch Chemical class 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- 239000008107 starch Chemical class 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 229920002678 cellulose Chemical class 0.000 claims description 4
- 239000001913 cellulose Chemical class 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical class O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 238000009491 slugging Methods 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 206010016807 Fluid retention Diseases 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000013543 active substance Substances 0.000 description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940126534 drug product Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 102000004136 Vasopressin Receptors Human genes 0.000 description 4
- 108090000643 Vasopressin Receptors Proteins 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101800001144 Arg-vasopressin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 7-chloro-2, 3,4,5- tetrahydro-5-hydroxy-lH-l-benzazepin-l-yl Chemical group 0.000 description 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000012254 powdered material Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 231100001127 band 4 compound Toxicity 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940077276 samsca Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising tolvaptan or one of its pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient manufactured by using dry granulation with improved pharmaceutical characteristics to obtain proper release profiles in three different physiological media of gastrointestinal tract.
- Arginine vasopressin is a neuropeptide synthesized in the para- ventricular and supraoptic nuclei of the hypothalamus, transported to the posterior pituitary gland and released into general circulation. It actively plays role to the regulation of water and solute excretion by the kidney, as well as blood pressure control and associated disorders such as congestive heart failure (CHF), liver cirrhosis, and syndrome of inappropriate antidiuretic hormone (SIADH) secretion.
- CHF congestive heart failure
- SIADH syndrome of inappropriate antidiuretic hormone
- Tolvaptan is indicated for the treatment of hypervolemic and euvolemic hyponatremia and for the prevention of hyponatremia.
- a selective vasopressin V2 receptor antagonist can be used for minimizing the effects of the increased AVP levels and reduce water retention without disturbing electrolytic balance.
- Tolvaptan is a non-peptide, selective vasopressin V2-receptor antagonist with affinity for the V2 receptor that is 1.8 time that of native arginine vasopressin (AVP). It selectively inhibits AVP induced water reabsorption at the renal collecting ducts by blocking V2 receptors located therein, which increased water excretion without any change in electrolyte excretion is occurred.
- AVP native arginine vasopressin
- Tolvaptan molecule has a racemic nature and the chemical name is ( ⁇ )-4’-[(7-chloro-2, 3,4,5- tetrahydro-5-hydroxy-lH-l-benzazepin-l-yl) carbonyl] -o-tolu-m-toluidide.
- the molecular formula is C26H25CIN2O3 and the compound has a molecular weight of 448.9 g/mol.
- Tolvaptan appeal's as a white crystalline powder and non-hygroscopic and exhibits low and pH independent water solubility. Tolvaptan is classified as Biopharmaceutical Classification System (BCS) IV drug.
- BCS Biopharmaceutical Classification System
- Tolvaptan and its pharmaceutically acceptable salts thereof first have been described in EP1028111 numbered patent document by Otsuka Pharmaceutical Co. for treatment of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin parasecretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokaliemia, diabetic, and circulation disorder.
- SIADH vasopressin parasecretion syndrome
- Tolvaptan was firstly commercially authorized by U.S. Food&Drug Administration in August 2009. The medicinal product of it been launched in the immediate release tablet dosage form under the name of the SAMSCA® in the strength of 15 mg and 30 mg which is used for the treatment of clinically significant a (serum sodium ⁇ 125 niEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), in patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
- a serum sodium ⁇ 125 niEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction
- SIADH Syndrome of Inappropriate Antidiuretic Hormone
- ADPKD autosomal dominant polycystic kidney disease
- EP2167046 relates to solid pharmaceutical composition
- solid pharmaceutical composition comprising tolvaptan or a pharmaceutically acceptable salt thereof, hydroxypropylcellulose containing a hydroxypropyl group in an amount of 50 wt% or greater; and at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 pm, and a 90% cumulative particle diameter of 100 to 200 pm manufactured by wet granulation method.
- EP2961383 relates to a suspension for oral pharmaceutical composition comprising amorphous tolvaptan, hydroxypropyl methylcellulose (HPMC) and a water. This dosage form is a suspension.
- JPH1121241 relates to a pharmaceutical composition
- amorphous tolvaptan prepared by dissolving with hydroxypropyl cellulose in an organic solvent and spray-drying the mixture to obtain a powder. This pre-study is performed to keep the tolvaptan molecule in stable.
- WO2014068586 relates to solid pharmaceutical composition
- solid pharmaceutical composition comprising tolvaptan or a pharmaceutically acceptable salt thereof, a polymer selected from povidone; graft co-polymer of polyethylene glycol, polyvinylcaprolactam and polyvinylacetate; and combinations thereof manufactured by fluid bed top spray granulation.
- This pre-study is also a pre-treatment process for a possible unstable situation.
- EP2586464 relates to solid pharmaceutical composition
- solid pharmaceutical composition comprising amorphous tolvaptan dissolved in an organic solvent and crosslinked polyvinylpyrrolidone, wherein the ratio of the active ingredient tolvaptan and the cross-linked polyvinylpyrrolidone by weight is 1:0.1-10.
- W02020122670 relates to pharmaceutical composition
- pharmaceutical composition comprising tolvaptan or a pharmaceutically acceptable salt thereof, polyvinylpyrrolidone used as a water penetration enhancer and at least one from the group consisting of methylene chloride and ethanol used as an organic solvent for dissolving tolvaptan and polyvinylpyrrolidone.
- CN 109646391 relates to a sustained release pharmaceutical composition
- a sustained release pharmaceutical composition comprising tolvaptan, hypromellose and at least one excipient, wherein the amount of hypromellose is between 30% and 45% of the total amount of the preparation with having viscosity ranges from 50 mPas to 10,000 mPas.
- Tolvaptan active substance is a BCS IV drug and due to this it is poorly soluble in water and the solubility is poor across all pH ranges. Thus, it is expected to have low absorption due to poor solubility.
- following single dose of 30 to 480 mg it is rapidly absorbed in healthy volunteers with a median time to peak plasma concentrations of about 2 hours.
- the absolute bioavailability is about 56% with close relative bioavailability between different dose strength.
- the mean elimination half-life is 7.8 hour.
- plasma protein is extensive (99%) and it bound mainly to serum albumin and al-acid glycoprotein.
- the inventors of the present invention have developed a pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient in the immediate release dosage form manufactured by using dry granulation to obtain suitable release profiles in three different physiological media of gastrointestinal tract with improved pharmaceutical characteristics of solubility and flowability.
- the object of this invention is to develop a pharmaceutical composition comprising a therapeutically effective amount of amorphous tolvaptan in the immediate release dosage form, with a dedicated manufacturing process.
- amorphous tolvaptan is known to be poorly soluble in physiological pH range.
- it is the objective of the present invention is to provide a pharmaceutical composition comprising amorphous tolvaptan with improved solubility.
- the utilization of the amorphous form can increase the solubility of tolvaptan in physiological pH range.
- the amorphous tolvaptan is unstable and the flowability is very challenging to overcome.
- Another object of the present invention is related to a pharmaceutical composition
- a pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient manufactured by using dry granulation where obtained granules are manufactured without using moisture, solvents and heat and a pre-treatment to get a solid dispersion or composite.
- Another object of the present invention is related to a pharmaceutical composition
- a pharmaceutical composition comprising the active ingredient, diluents, binder, disintegrant, lubricant and glidant with respect to the intended form of administration.
- Amorphous tolvaptan has another restriction during development pharmaceutical such as having quite poor flowability property.
- colloidal silicon dioxide is used as glidant and the composition is manufactured by using the dry granulation process.
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient manufactured by using dry granulation to release more than 85% of the amorphous tolvaptan in 15 minutes in 0.22% sodium lauryl sulphate (SLS) in pH 1.2, pH 4.5, pH 6.8 buffer solutions simulating GI tract conditions at 37 ⁇ 0.5°C using USP type II (paddle) apparatus rotating at 50 rpm.
- SLS sodium lauryl sulphate
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipients developed in the immediate release dosage form wherein the prepared composition is manufactured with the most proper manufacturing process with critical parameters.
- Direct compression refers to being a relatively quick process where the powdered materials are compressed are mixed well and performed the tablet compression without requiring further granulation steps. Thus, it is preferred to use over wet or dry granulation because of quick processing time. However, it has some challenges when the drug has poor solubility and flowability characteristics during proceeding steps. Therefore, characterisation of tolvaptan active substance was investigated.
- Tolvaptan active substance is known to be practically insolubility in water and exhibit poor solubility (approximately 0.01 mg/250 mL) across all pH ranges stated in Table 1.
- tolvaptan is poorly soluble and in addition, permeability is low as to be expected due to BCS IV drug characterisation.
- tolvaptan is preferred to be used in amorphous form.
- the amorphous form is one of the promising strategy to overcome the poor oral bioavailability associated with BCS Class IV compounds due to having a higher free energy than its crystalline counterpart, and that will increase the apparent solubility and dissolution rate. However, it tends to crystallize over time due to being thermodynamically unstable and this crystallization effect is evaluated with in-vitro dissolution study.
- wet granulation is preferred to be experienced that refers to converting a powder blend into granules having suitable flow and being cohesive properties for tableting to achieve the desired properties for subsequent processes.
- the granulating solution can be a solvent or a solution comprising a binder or granulating agent to used to ensure particle adhesion once the granule is dried.
- a pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient was designed to be able use wet granulation manufacturing process.
- a pharmaceutical composition for oral administration is a pharmaceutical composition for oral administration.
- Suitable solid oral dosage forms are selected from the group comprising tablets, capsules, granules, powders, and pellet or unit dose packets, preferably the solid oral dosage form is tablet.
- a pharmaceutical composition containing amorphous tolvaptan manufactured by using wet granulation process in tablet dosage form to comprise pharmaceutically acceptable excipients in function of binder, disintegrant, surfactant, lubricants and granulation solvent selected as to be the most suitable ones with respect to the intended form of administration.
- the diluent may include, but are not limited to dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
- diluents are lactose and microcrystalline cellulose.
- the binder may include, but are not limited to lactose monohydrate, starch, pregelatinized starch, cellulose or cellulose derivatives, povidone, sucrose, polyethylene glycol, or mixtures thereof.
- the binder is pregelatinized starch.
- the disintegrant may include, but is not limited to calcium, croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
- the disintegrants are croscarmellose sodium.
- the surfactant may include, but is not limited to betain, quaternary ammonium salts, polysorbates, poloxamer.
- the surfactant is a poloxamer.
- the lubricants may include, but are not limited to sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
- the lubricants are talc and magnesium stearate.
- the granulation solvent may include, but are not limited to methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, dichloromethane, dichloroethane, chloroform, or carbon tetrachloride; and mixed solvents of those.
- the granulation solvents are ethanol and dichloromethane.
- a mixed solvent comprising dichloromethane and ethanol is in the ratio of 4:1.
- Another object of the present invention is to provide a pharmaceutical compositions containing tolvaptan wherein the total weight of the tolvaptan is less than 20% w/w by total tablet weight.
- the proposed embodiment based on the invention provides an immediate release pharmaceutical composition wherein the amounts in w/w% by weight of the total composition are as stated in the Table 2 below:
- Example 1 for immediate release pharmaceutical
- Amorphous tolvaptan, croscarmellose sodium, microcrystalline cellulose, lactose and pregelatinized starch were screened through a proper sieve and transferred into cubic mixer and stirred,
- Poloxamer was dissolved in sufficient quantity of dichloromethane and ethanol mixture
- Step (3) The preparation in Step (1) was added to solution in Step (2) to perform high-shear granulation process
- the dissolution test is carried out in 0.22% sodium lauryl sulphate (SLS) aqueous solution.
- SLS sodium lauryl sulphate
- Other conditions are defined as; volume of dissolution media is 900 ml, temperature is 37°C ⁇ 0.5°C, rotation speed is 50 rpm, apparatus is paddle and the duration of dissolution study is 60-minute.
- the amount of dissolved active ingredient over time was determined by HPLC.
- Example 1 It is observed that the release pattern of Example 1 was remarkably slower than the reference drug product.
- the similarity factor f2 value is a tool to measure similarity of two products. This value should be between 50-100 to be defined as similar and closer this value to 100 means scale of similarity is high.
- the similarity factor f2 of Example 1 and the reference drug product was calculated as 17 since less than 50, the products compared were not similar.
- the desired concentration was not achieved and the dissolved amorphous tolvaptan was less than 40% within 60 minutes.
- the physicochemical properties of amorphous tolvaptan such as solubility properties were considered to formulate by optimizing critical parameters to obtain successful drug composition which could reach the required therapeutic amount in a specified time.
- the manufacturing process of the pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient was altered as using dry granulation. This process was not preferred considering disadvantages of tolvaptan in solubility and processability points of view. To improve these physicochemical properties, formulation design and details of manufacturing process should be proposed carefully.
- Dry granulation refers to obtaining granules without wetting and subsequent drying processes to be avoided some issues related to wet granulation where the powdered materials comprising active substance with or without at least one pharmaceutically acceptable excipient are mixed and aggregated under high pressure which are then sieved before the addition of other ingredients to obtain final compression.
- Example 2 the percentage of therapeutically effective dose of amorphous tolvaptan and the amount of pharmaceutically acceptable excipients were adjusted.
- tolvaptan active substance bulk density and tapped density were found as 0.19 g/ml and 0.34 g/ml, respectively and compressibility index and Hausner ratio were 44.00 and 1.738, respectively.
- the glidant may include, but is not limited to colloidal silicon dioxide, talc, magnesium stearate or the like.
- the glidant is a colloidal silicon dioxide.
- the tablet composition of the present invention comprising the following ingredients, based on the total weight of the composition:
- a therapeutically effective dose of amorphous tolvaptan was adjusted in an amount of from 5% to 8% w/w by total weight of composition.
- Microcrystalline cellulose and lactose used as diluent in a mixture thereof were adjusted in an amount of from 70% to 78% w/w by total weight of composition.
- Pregelatinized starch used as binder and croscarmellose sodium used as disintegrant were adjusted in an amount of from 8% to 10% w/w by total weight of composition.
- Colloidal silicon dioxide used as glidant was added in an amount of from 0.0% to 1.0% w/w by total weight of composition.
- Poloxamer used as surfactant was removed from the composition.
- Example 2 The formulation of proposed embodiment identified as Example 2 is given in the Table 5.
- Example 2 The release pattern of Example 2 was similar to the reference drug product, in which the similarity factor f2 were calculated as 62.
- SLS sodium lauryl sulphate
- Example 2 Based on the results presented in Table 6 above, the release patterns of Example 2 in 0.22% sodium lauryl sulphate (SLS) in pH 1.2, pH 4.5 acetate buffer and pH 6.8 phosphate buffer were similar to the reference drug product, in which the similarity factor f2 were calculated for all buffer solutions as 64.1, 72.2 and 84 respectively.
- SLS sodium lauryl sulphate
- the developed pharmaceutical composition comprising amorphous tolvaptan and at least one pharmaceutically acceptable excipient in the immediate release dosage form manufactured by using dry granulation method where the composition was compressed into tablets between 150 kP to 200 kP to get similar dissolution profile in 0.22% sodium lauryl sulphate (SLS) in pH 1.2, pH 4.5 acetate buffer and pH 6.8 phosphate buffer to the reference drug product.
- SLS sodium lauryl sulphate
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant du tolvaptan ou l'un de ses sels pharmaceutiquement acceptables et au moins un excipient pharmaceutiquement acceptable fabriqué en utilisant une granulation sèche avec des caractéristiques pharmaceutiques améliorées pour obtenir des profils de libération appropriés dans trois milieux physiologiques différents du tractus gastro-intestinal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2021/051629 WO2023128905A1 (fr) | 2021-12-30 | 2021-12-30 | Composition pharmaceutique comprenant du tolvaptan amorphe |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2021/051629 WO2023128905A1 (fr) | 2021-12-30 | 2021-12-30 | Composition pharmaceutique comprenant du tolvaptan amorphe |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023128905A1 true WO2023128905A1 (fr) | 2023-07-06 |
Family
ID=87000092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2021/051629 WO2023128905A1 (fr) | 2021-12-30 | 2021-12-30 | Composition pharmaceutique comprenant du tolvaptan amorphe |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023128905A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110165249A1 (en) * | 2008-09-05 | 2011-07-07 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation |
CN102512393A (zh) * | 2011-12-19 | 2012-06-27 | 浙江华海药业股份有限公司 | 一种托伐普坦的口腔崩解片 |
CN111888335A (zh) * | 2020-08-21 | 2020-11-06 | 福安药业集团重庆礼邦药物开发有限公司 | 一种托伐普坦的药物固体制剂及制备方法 |
-
2021
- 2021-12-30 WO PCT/TR2021/051629 patent/WO2023128905A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110165249A1 (en) * | 2008-09-05 | 2011-07-07 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation |
CN102512393A (zh) * | 2011-12-19 | 2012-06-27 | 浙江华海药业股份有限公司 | 一种托伐普坦的口腔崩解片 |
CN111888335A (zh) * | 2020-08-21 | 2020-11-06 | 福安药业集团重庆礼邦药物开发有限公司 | 一种托伐普坦的药物固体制剂及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6517871B1 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
US6558699B2 (en) | High drug load immediate and modified release oral dosage formulations and processes for their manufacture | |
US6630498B2 (en) | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation | |
US20090324718A1 (en) | Imatinib compositions | |
CA2672402A1 (fr) | Dispersion solide d'un antagoniste de la neurokinine | |
AU750611B2 (en) | High drug load immediate and modified release oral dosage formulations and processes for their manufacture | |
AU2890999A (en) | Novel compositions of eprosartan | |
US20140271855A1 (en) | Sovaprevir tablets | |
US20090030057A1 (en) | Pharmaceutical composition of telmisartan | |
AU739295B2 (en) | Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation | |
WO2023128905A1 (fr) | Composition pharmaceutique comprenant du tolvaptan amorphe | |
US20220387418A1 (en) | Pharmaceutical compositions of cabozantinib | |
WO2024136768A1 (fr) | Compositions pharmaceutiques stables contenant du tolvaptan amorphe | |
WO2023128903A1 (fr) | Procédé de fabrication amélioré pour formulations comprenant du tolvaptan amorphe | |
KR20110031226A (ko) | 에프로사르탄 조성물 | |
WO2023227997A1 (fr) | Composition pharmaceutique contenant une combinaison d'azilsartan et de chlorthalidone et son procédé de préparation | |
TR2023006078T2 (tr) | Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu | |
WO2024096839A1 (fr) | Composition pharmaceutique comprenant une dispersion solide d'empagliflozine | |
WO2024118556A1 (fr) | Dispersion solide comprenant du 2-[3-[4-(lh-indazol-5-ylamino) quinazolin-2-yl] phénoxy]-n-propan-2-yl-acétamide amorphe | |
US20070249694A1 (en) | Metaxalone formulations and methods for the preparation thereof | |
WO2024096838A1 (fr) | Composition pharmaceutique comprenant une dispersion solide d'empagliflozine | |
WO2022162687A1 (fr) | Compositions pharmaceutiques comprenant du nilotinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21970150 Country of ref document: EP Kind code of ref document: A1 |